TrialAdvances in therapy2026

Efficacy and Safety of Switching to Picankibart from Non-interleukin-23 Subunit p19 Inhibitors in Patients with Plaque Psoriasis: A Multicenter, Open-Label, Phase 2 Trial.

Qing Yang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.